These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study.
    Author: Poyurovsky M, Shardorodsky M, Fuchs C, Schneidman M, Weizman A.
    Journal: Br J Psychiatry; 1999 Mar; 174():238-42. PubMed ID: 10448449.
    Abstract:
    BACKGROUND: Serotonin (5-HT):dopamine imbalance may underlie neuroleptic-induced akathisia. AIM: To evaluate the efficacy of the 5-HT2 antagonist, mianserin in neuroleptic-induced akathisia. METHODS: Thirty neuroleptic-treated patients with schizophrenia were randomly allocated in a double-blind design to receive either mianserin (15 mg/day) or placebo for five days. Patients were assessed at baseline and on Days 3 and 5 by the Barnes Akathisia Scale (BARS), as well as by other relevant clinical rating scales. RESULTS: Compared with the placebo group, the mianserin-treated patients showed a significant reduction in all four BARS subscales by Day 5, with mean reductions in the BARS global score of 9.9% and 52.2%, respectively (P = 0.006). Response to treatment (a reduction of at least two points on the BARS global subscale), was noted in six patients (40%) in the mianserin group and only one patient (9.1%) in the placebo group (P = 0.04, log odds ratio 2.23). CONCLUSIONS: Mianserin at a low dose may be a promising therapeutic option for patients with acute neuroleptic-induced akathisia.
    [Abstract] [Full Text] [Related] [New Search]